D. Vickery

发表

Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

T. Choueiri, D. McDermott, R. Perini, 2021, Journal of Clinical Oncology.

Skin Concentrations and Pharmacokinetics of Posaconazole after Oral Administration

A. Tavakkol, G. Krishna, M. Martinho, 2010, Antimicrobial Agents and Chemotherapy.

Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers

G. Krishna, Lei Ma, S. Komjathy, 2009, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers

Jay B. Varkey, J. Perfect, G. Krishna, 2009, Antimicrobial Agents and Chemotherapy.

Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin

G. Krishna, Lei Ma, E. Beresford, 2011, Journal of clinical pharmacology.

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.

R. Figlin, T. Choueiri, M. Michaelson, 2023, The Lancet. Oncology.

1447O Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003

R. Figlin, R. Perini, A. Roy, 2022, Annals of Oncology.

656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

T. Choueiri, D. McDermott, R. Perini, 2021, Annals of Oncology.

MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.

T. Powles, T. Choueiri, B. Rini, 2021 .

LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

E. Verzoni, L. Albiges, D. Vickery, 2023, Annals of Oncology.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

A. Poprach, G. De Velasco, L. Albiges, 2024, The New England journal of medicine.